Cozad Asset Management Inc. Acquires 3,391 Shares of Johnson & Johnson (NYSE:JNJ)

Cozad Asset Management Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 25.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,520 shares of the company’s stock after purchasing an additional 3,391 shares during the quarter. Cozad Asset Management Inc.’s holdings in Johnson & Johnson were worth $2,389,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Horizon Kinetics Asset Management LLC raised its holdings in shares of Johnson & Johnson by 0.9% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 19,602 shares of the company’s stock worth $2,835,000 after acquiring an additional 174 shares in the last quarter. Curio Wealth LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $104,000. Cassady Schiller Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.6% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 8,154 shares of the company’s stock worth $1,179,000 after acquiring an additional 128 shares in the last quarter. TCTC Holdings LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the 4th quarter. TCTC Holdings LLC now owns 61,153 shares of the company’s stock worth $8,844,000 after acquiring an additional 319 shares in the last quarter. Finally, Arbor Capital Management Inc. ADV raised its holdings in shares of Johnson & Johnson by 4.5% during the 4th quarter. Arbor Capital Management Inc. ADV now owns 11,382 shares of the company’s stock worth $1,722,000 after acquiring an additional 494 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Citigroup decreased their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Leerink Partners decreased their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Finally, Bank of America increased their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $162.94 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The business’s fifty day simple moving average is $154.98 and its 200-day simple moving average is $156.27. The company has a market capitalization of $392.29 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the company earned $2.29 EPS. The business’s revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.